Literature DB >> 21930648

Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Peng Zhang1, Huaiyu Hu.   

Abstract

Genetic defects in like-glycosyltransferase (LARGE) cause congenital muscular dystrophy with central nervous system manifestations. The underlying molecular pathomechanism is the hypoglycosylation of α-dystroglycan (α-DG), which is evidenced by diminished immunoreactivity to IIH6C4 and VIA4-1, antibodies that recognize carbohydrate epitopes. Previous studies indicate that LARGE participates in the formation of a phosphoryl glycan branch on O-linked mannose or it modifies complex N- and mucin O-glycans. In this study, we overexpressed LARGE in neural stem cells deficient in protein O-mannosyltransferase 2 (POMT2), an enzyme required for O-mannosyl glycosylation. The results showed that overexpressing LARGE did not lead to hyperglycosylation of α-DG in POMT2 knockout (KO) cells but did generate IIH6C4 and VIA4-1 immunoreactivity and laminin-binding activity. Additionally, overexpressing LARGE in cells deficient in both POMT2 and α-DG generated laminin-binding IIH6C4 immunoreactivity. These results indicate that LARGE expression resulted in the glycosylation of proteins other than α-DG in the absence of O-mannosyl glycosylation. The IIH6C4 immunoreactivity generated in double-KO cells was largely removed by treatment either with peptide N-glycosidase F or with cold aqueous hydrofluoric acid, suggesting that LARGE expression caused phosphoryl glycosylation of N-glycans. However, the glycosylation of α-DG by LARGE is dependent on POMT2, indicating that LARGE expression only modifies O-linked mannosyl glycans of α-DG. Thus, LARGE expression mediates the phosphoryl glycosylation of not only O-mannosyl glycans including those on α-DG but also N-glycans on proteins other than α-DG.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930648      PMCID: PMC3255506          DOI: 10.1093/glycob/cwr131

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  63 in total

1.  A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype.

Authors:  D Beltrán-Valero de Bernabé; H van Bokhoven; E van Beusekom; W Van den Akker; S Kant; W B Dobyns; B Cormand; S Currier; B Hamel; B Talim; H Topaloglu; H G Brunner
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

2.  Intragenic rearrangements in LARGE and POMGNT1 genes in severe dystroglycanopathies.

Authors:  S Vuillaumier-Barrot; C Bouchet-Seraphin; M Chelbi; A Eude-Caye; E Charluteau; C Besson; S Quentin; L Devisme; C Le Bizec; P Landrieu; A Goldenberg; K Maincent; P Loget; O Boute; B Gilbert-Dussardier; F Encha-Razavi; M Gonzales; B Grandchamp; N Seta
Journal:  Neuromuscul Disord       Date:  2011-07-02       Impact factor: 4.296

3.  Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies.

Authors:  Daniel E Michele; Rita Barresi; Motoi Kanagawa; Fumiaki Saito; Ronald D Cohn; Jakob S Satz; James Dollar; Ichizo Nishino; Richard I Kelley; Hannu Somer; Volker Straub; Katherine D Mathews; Steven A Moore; Kevin P Campbell
Journal:  Nature       Date:  2002-07-25       Impact factor: 49.962

4.  Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development.

Authors:  Satoshi Takeda; Mari Kondo; Junko Sasaki; Hiroki Kurahashi; Hiroki Kano; Ken Arai; Kazuyo Misaki; Takehiko Fukui; Kazuhiro Kobayashi; Masaji Tachikawa; Michihiro Imamura; Yusuke Nakamura; Teruo Shimizu; Tatsufumi Murakami; Yoshihide Sunada; Takashi Fujikado; Kiichiro Matsumura; Toshio Terashima; Tatsushi Toda
Journal:  Hum Mol Genet       Date:  2003-06-15       Impact factor: 6.150

5.  Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.

Authors:  Cheryl Longman; Martin Brockington; Silvia Torelli; Cecilia Jimenez-Mallebrera; Colin Kennedy; Nofal Khalil; Lucy Feng; Ravindra K Saran; Thomas Voit; Luciano Merlini; Caroline A Sewry; Susan C Brown; Francesco Muntoni
Journal:  Hum Mol Genet       Date:  2003-09-09       Impact factor: 6.150

6.  Molecular cloning and characterization of human GnT-IX, a novel beta1,6-N-acetylglucosaminyltransferase that is specifically expressed in the brain.

Authors:  Kei-ichiro Inamori; Takeshi Endo; Yoshihito Ide; Shigeru Fujii; Jianguo Gu; Koichi Honke; Naoyuki Taniguchi
Journal:  J Biol Chem       Date:  2003-08-26       Impact factor: 5.157

7.  Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle - eye - brain disorders.

Authors:  Paul J Holzfeind; Prabhjit K Grewal; Herbert A Reitsamer; Jasmin Kechvar; Hans Lassmann; Harald Hoeger; Jane E Hewitt; Reginald E Bittner
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

8.  Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome.

Authors:  Daniel Beltrán-Valero de Bernabé; Sophie Currier; Alice Steinbrecher; Jacopo Celli; Ellen van Beusekom; Bert van der Zwaag; Hülya Kayserili; Luciano Merlini; David Chitayat; William B Dobyns; Bru Cormand; Ana-Elina Lehesjoki; Jesús Cruces; Thomas Voit; Christopher A Walsh; Hans van Bokhoven; Han G Brunner
Journal:  Am J Hum Genet       Date:  2002-10-04       Impact factor: 11.025

9.  Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity.

Authors:  Hiroshi Manya; Atsuro Chiba; Aruto Yoshida; Xiaohui Wang; Yasunori Chiba; Yoshifumi Jigami; Richard U Margolis; Tamao Endo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

10.  Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage.

Authors:  Jessica A Gorski; Tiffany Talley; Mengsheng Qiu; Luis Puelles; John L R Rubenstein; Kevin R Jones
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more
  21 in total

1.  Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.

Authors:  Charles H Vannoy; Lei Xu; Elizabeth Keramaris; Pei Lu; Xiao Xiao; Qi Long Lu
Journal:  Hum Gene Ther Methods       Date:  2014-05-02       Impact factor: 2.396

Review 2.  Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex.

Authors:  Dewayne Townsend
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

Review 3.  Recent advancements in understanding mammalian O-mannosylation.

Authors:  M Osman Sheikh; Stephanie M Halmo; Lance Wells
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

4.  Differentiation-related glycan epitopes identify discrete domains of the muscle glycocalyx.

Authors:  Brian J McMorran; Francis E McCarthy; Elizabeth M Gibbs; Mabel Pang; Jamie L Marshall; Alison V Nairn; Kelley W Moremen; Rachelle H Crosbie-Watson; Linda G Baum
Journal:  Glycobiology       Date:  2016-05-28       Impact factor: 4.313

Review 5.  Dissecting the molecular basis of the role of the O-mannosylation pathway in disease: α-dystroglycan and forms of muscular dystrophy.

Authors:  David Live; Lance Wells; Geert-Jan Boons
Journal:  Chembiochem       Date:  2013-11-07       Impact factor: 3.164

6.  Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy.

Authors:  Peng Zhang; Yuan Yang; Joseph Candiello; Trista L Thorn; Noel Gray; Willi M Halfter; Huaiyu Hu
Journal:  Matrix Biol       Date:  2013-02-27       Impact factor: 11.583

7.  Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.

Authors:  Naoyuki Kuwabara; Hiroshi Manya; Takeyuki Yamada; Hiroaki Tateno; Motoi Kanagawa; Kazuhiro Kobayashi; Keiko Akasaka-Manya; Yuriko Hirose; Mamoru Mizuno; Mitsunori Ikeguchi; Tatsushi Toda; Jun Hirabayashi; Toshiya Senda; Tamao Endo; Ryuichi Kato
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-04       Impact factor: 11.205

8.  Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy.

Authors:  Miao Yu; Yonglin He; Kejian Wang; Peng Zhang; Shengle Zhang; Huaiyu Hu
Journal:  Hum Gene Ther       Date:  2013-03       Impact factor: 5.695

9.  The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice.

Authors:  Charlotte Whitmore; Marta Fernandez-Fuente; Helen Booler; Callum Parr; Manoli Kavishwar; Attia Ashraf; Erica Lacey; Jihee Kim; Rebecca Terry; Mark R Ackroyd; Kim E Wells; Francesco Muntoni; Dominic J Wells; Susan C Brown
Journal:  Hum Mol Genet       Date:  2013-11-13       Impact factor: 6.150

10.  Identification of antithrombin-modulating genes. Role of LARGE, a gene encoding a bifunctional glycosyltransferase, in the secretion of proteins?

Authors:  María Eugenia de la Morena-Barrio; Alfonso Buil; Ana Isabel Antón; Irene Martínez-Martínez; Antonia Miñano; Ricardo Gutiérrez-Gallego; José Navarro-Fernández; Sonia Aguila; Juan Carlos Souto; Vicente Vicente; José Manuel Soria; Javier Corral
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.